{"id":"NCT04878055","sponsor":"Domp√© Farmaceutici S.p.A","briefTitle":"Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.","officialTitle":"A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-02-14","primaryCompletion":"2021-09-30","completion":"2021-10-31","firstPosted":"2021-05-07","resultsPosted":"2024-06-13","lastUpdate":"2024-06-13"},"enrollment":287,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pneumonia, Viral"],"interventions":[{"type":"DRUG","name":"Reparixin","otherNames":["DF 1681Y"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Reparixin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study objective is to assess Efficacy and safety of Reparixin treatment as compared to placebo (both on top of standard treatment) in adult patients with severe COVID-19 pneumonia.","primaryOutcome":{"measure":"Proportion of Patients Alive and Free of Respiratory Failure at Day 28","timeFrame":"At day 28","effectByArm":[{"arm":"Reparixin","deltaMin":152,"sd":null},{"arm":"Placebo","deltaMin":71,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.216"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["United States","Italy"]},"refs":{"pmids":["37798468"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":182},"commonTop":["Constipation","Insomnia","Anxiety","Urinary tract infection","Tachycardia"]}}